Welcome to our dedicated page for Dianthus Therapeutics SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dianthus Therapeutics, Inc. (DNTH) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company listed on The Nasdaq Capital Market under the symbol DNTH, Dianthus uses SEC reports to communicate material events, financial results, and key agreements related to its development of therapies for severe autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results, positive top-line Phase 2 data for claseprubart (DNTH103) in generalized myasthenia gravis, and an underwriting agreement for an underwritten public offering of common stock and pre-funded warrants. Other 8-K filings describe a license and collaboration agreement with Nanjing Leads Biolabs Co. Ltd. for DNTH212 (LBL-047), outlining the exclusive license outside Greater China, milestone and royalty structure, and joint governance for development and commercialization.
Through this page, users can review how Dianthus reports its cash position, research and development expenses, and other financial metrics in connection with clinical-stage operations. Filings also document regulatory and corporate milestones that affect the company’s pipeline of investigational agents, including claseprubart and DNTH212, both of which are described as not approved as therapies in any indication in any jurisdiction worldwide.
Stock Titan enhances access to these filings with AI-powered summaries that explain the main points of lengthy documents, helping readers quickly understand material agreements, capital raises, and clinical or financial updates. Investors and researchers can use this resource to follow DNTH’s official disclosures, track changes over time, and connect specific filings to press releases and clinical news about the company’s autoimmune-focused programs.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. He exercised options for 8,224 shares of common stock at an exercise price of $17.88 per share, then sold 8,224 shares of common stock at a weighted average price of $89.84 per share.
The filing shows 71,776 stock options remaining following the derivative transaction and 0 shares of common stock held directly after the sale. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.
Ryan Savitz submitted a Form 144 notice to sell 8,224 shares of Common Stock pursuant to an exercise of stock options dated 04/09/2026, with a cash amount shown as $719,435.52. The filing also records prior 10b5-1 sales of 114,367 shares on 03/31/2026 for $9,492,532.35.
Dianthus Therapeutics, Inc. is calling a virtual 2026 annual stockholders meeting on May 21, 2026 at 9:00 a.m. Eastern Time. Holders of 54,448,771 common shares of record on March 30, 2026 may vote online after registering at the meeting website.
Stockholders will elect three Class II directors to serve until 2029, cast an advisory vote on executive compensation, and ratify Deloitte & Touche LLP as independent auditor for 2026. The proxy details a staggered, largely independent board, committee structures, director pay in cash and stock options, and performance-based executive pay tied to drug development milestones and a reported 649% total stockholder return since the 2023 reverse merger.
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options and sold the resulting shares. On March 31, 2026, he exercised options to acquire 114,367 shares of common stock, including 74,367 shares at an exercise price of $8.44 and 40,000 shares at $17.88 per share. He then sold 114,367 shares of common stock in a series of open-market transactions at weighted average prices ranging from about $78.33 to $85.54 per share, under a Rule 10b5-1 trading plan adopted on December 30, 2025. Following these transactions, the filing shows he directly owns no shares of common stock.
Dianthus Therapeutics director Paula Soteropoulos exercised stock options and sold the resulting shares. On March 31, 2026, she exercised options for 599 shares of common stock at $8.44 per share and immediately sold all 599 shares at $80.11 per share in an open-market transaction.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, the filing shows 0 common shares held directly from this transaction.
Insider notice of planned sale and recent 10b5-1 disposals. The filing reports 1,198 shares of Common Stock to be sold on 03/31/2026 following an exercise of stock options for cash. It also discloses 10b5-1 sales completed on 03/24/2026 totaling 27,594 shares for $2,153,579.25.
Dianthus Therapeutics director Paula Soteropoulos exercised stock options for 27,594 shares of common stock at an exercise price of $8.44 per share and immediately sold the same 27,594 shares in an open-market transaction at $78.05 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. Following the sale, she held no shares of common stock directly.
Dianthus Therapeutics reports that in the first quarter of 2026 it proposed, and in March 2026 received, written FDA agreement to three changes across all ongoing and planned claseprubart trials. Anti-nuclear antibodies will no longer be used as a screening criterion or routinely tested, and the hypothetical safety risk is reclassified from systemic lupus erythematosus to drug-induced lupus. The company notes there have been no cases of SLE or DIL in any claseprubart program to date.
Dianthus’ investor presentation highlights claseprubart and DNTH212 as pipeline-in-a-product autoimmune therapies, with strong Phase 2 gMG data, an early Phase 3 CIDP “GO” decision, and broad neuromuscular and autoimmune indications under study. The company cites a strong financial position with approximately $1.2 billion of pro forma cash and runway expected into 2030, supporting multiple planned milestones, including a Phase 3 gMG trial initiation, Phase 2 MMN data, CAPTIVATE Part B readout guidance in CIDP, and Phase 1 top-line results for DNTH212.